Related Experiment Videos
[Peripheral arteriography at an advanced age using a new contrast agent]
Rontgen-Blatter; Zeitschrift Fur Rontgen-Technik Und Medizinisch-Wissenschaftliche Photographie
|April 1, 1984
Summary
A new non-ionic contrast agent, Jopamidol, showed excellent safety in over 200 patients undergoing angiographic examinations. The study found no serious side-effects, including cardiovascular or renal issues, and minimal patient discomfort.
Area of Science:
- Radiology
- Medical Imaging
- Pharmacology
Context:
- Angiography is a crucial diagnostic imaging technique.
- Assessing the safety and efficacy of contrast agents is vital for patient care.
- Older adult populations often have comorbidities that require careful consideration during medical procedures.
Purpose:
- To evaluate the safety and tolerability of a new non-ionic contrast agent, Jopamidol.
- To assess the incidence of adverse events, particularly cardiovascular and renal dysfunctions, following angiographic examinations using Jopamidol.
- To document subjective patient experiences with the new contrast agent.
Summary:
- A new non-ionic contrast agent, Jopamidol (300 mg iodine/ml), was administered in 492 arterial injections to over 200 patients (median age ~70 years) for angiographic examinations.
- No serious adverse events, including cardiovascular or renal complications, were observed.
- Most patients reported a lack of subjective discomfort during the procedure.
Impact:
- Jopamidol demonstrates a favorable safety profile for angiographic procedures, especially in elderly patients.
- The findings support the use of Jopamidol as a safe alternative contrast agent, potentially reducing patient-reported discomfort.
- This research contributes to the understanding of contrast agent safety in interventional radiology and cardiology.